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Application of the International Prognostic Scoring SystemRevised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia Leukemia (2014) 28, 185-189; doi:10.1038/leu. 2013.191 Therapy-related myeloid neoplasms (t-MN) occur in patients who received cytotoxic therapies for prior malignancy or, rarely, for non-malignant diseases. 1 With the improvement of chemotherapeutic regimens and supportive care measures, increased long-term cancer survivors have lead to an increased incidence of t-MN. t-MN, including therapy-related myelodysplastic syndromes (t-MDS) and therapy-related acute myeloid leukemia (t-AML), are clinically aggressive compared with their de novo counterparts. 2 Owing to a generally poor outcome of affected patients, 3 in the 2008 World Health Organization (WHO) classification, t-MDS and t-AML are not considered sufficiently distinctive and classified together under t-MN. 1 However, heterogeneous clinical outcomes have been observed, particularly within the t-MDS group, 4 and a prognostic model for t-MN would be relevant in risk-adapted therapeutic decisions. The classifications and risk-scoring systems for MDS including the French-American-British, WHO, International Prognostic Scoring System (IPSS) and WHO-based Prognostic Scoring System (WPSS) are largely based on cohorts of de novo MDS patients. Among these models, IPSS is the most broadly used and generally accepted system for de novo MDS. In practice, without a risk model available, patients with t-MDS are assigned an IPSS score such as de novo MDS. Recently, the IPSS has been revised (IPSS-R) 5 to incorporate new findings from the New Comprehensive Cytogenetic Scoring System (NCCSS) 6 and to utilize different strata for cytopenia(s) and bone marrow (BM) blasts. The IPSS-R has shown better predict values in de novo MDS and oligoblastic AML (o30% blasts). Notably, patients with therapy-related diseases again were excluded from the study cohort.
To test if the IPSS-R is applicable to t-MDS and oligoblastic t-AML patients, we searched the database of MD Anderson Cancer Center and Massachusetts General Hospital from 2000-2011 with institutional review board approvals. A total of 660 patients who met the strict WHO criteria for t-MN were identified. In keeping with the NCCSS and IPSS-R 5,6 studies, we included cases with BM blasts between 20 and 29%, and peripheral blood blasts o20% (oligoblastic t-AML), and excluded 137 patients with X30% BM blasts or X20% peripheral blood blasts. Of the remaining patients, we further excluded two patients with inv(16)(p13.1q22), six patients with t-MDS/MPN, Accepted article preview online 21 June 2013; advance online publication, 12 July 2013 Letters to the Editor one with no follow-up data and 103 patients with hematopoietic stem cell transplant (HSCT). The remaining 411 patients formed the study group, including 32 (7.8%) patients with oligoblastic t-AML and 379 patients (92.2%) with t-MDS. Treatment for t-MDS/oligoblastic t-AML was categorized as supportive care only (n ¼ 170, 41.4%); lower intensity therapies, including hypomethylating agents, low-dose chemotherapy, immunomodulating agents and investigational drugs (n ¼ 159, 38.7%); and induction chemotherapy (n ¼ 82, 20.0%). Prior therapies, complete blood counts, cytogenetics and the WHO categories are shown in Table1.
In this study, patient outcomes were assessed by overall survival (OS) and disease-specific survival (DSS). The rationale for using DSS as a second outcome parameter was to exclude deaths attributed to the primary cancer. In DSS analysis, patients who were alive (n ¼ 49) or died from causes other than t-MDS/AML (n ¼ 90) or undetermined causes (n ¼ 49) were censored. AML progression probability was calculated in patients with o20% BM blasts (t-MDS). Distributions of OS, DSS and AML progression probability were estimated by the Kaplan-Meier method. Univariate and multivariate Cox proportional hazards regression were performed to assess the IPSS-R variables, as well as additional parameters such as age, gender and type of cytotoxic therapy on survivals. All P-values are two-tailed with no adjustments for multiplicity. Statistical analysis was performed using SAS 9.3 for Windows.
The median follow-up was 10.2 months (range 0.1-146). The median OS was 10.3 months (95% CI: 8.7-12.2) and DSS was 17 months (95% CI: 13.4-21.1). In analysis of the IPSS-R variables, BM blast percentage, as a continuous variable, correlated significantly with OS and DSS (Supplementary Table1). In univariate analysis, significant differences in OS and DSS were observed in every BM blast category compared with the reference (0-2%), but not between any other two contiguous categories (Supplementary Table1). In multivariate analysis, both the 5-10% and 410-30% categories, but not the 42-o5% category, were significantly different from the reference for both OS and DSS; nor between any other contiguous categories (Table 2 ). These results suggest that in the presence of the other IPSS-R variables, a single 5% cutpoint for BM blasts may be most relevant for risk stratification. Hemoglobin level, as a continuous variable, correlated significantly with OS and DSS. Significant differences in OS and DSS were observed for both the 8-10 g/dl and o8 g/dl categories compared with the reference (X10 g/dl), but not between the 8-10 g/dl and o8 g/dl in univariate (Supplementary Table1) and multivariate analysis ( Table 2 ). These results suggest that a single hemoglobin cutpoint at 10 g/dl could be used, as significant differences between groups of patients with values o10 g/dl were not observed. Absolute neutrophil count (ANC) showed no significant associations with OS or DSS in univariate or multivariate analyses, either when ANC was used as a continuous or categorical variable (Table 2 and Supplementary Table 1 ). Platelet count, as a continuous variable, correlated significantly with OS and DSS. Patients with platelets o50 Â 10 9 /l, but not 50-100 Â 10 9 /l, had a significantly inferior OS and DSS to the reference (X100 Â 10 9 /l) in univariate (Supplementary Table1) and multivariate analysis ( Table 2 ). These results suggest that a single cutpoint for platelets of p50 Â 10 9 /l could be considered, as the categories above this level were not significantly different from one other. Karyotypic abnormalities were identified in 306 of 396 (77.3%) patients, with frequent partial or complete loss of chromosome 5 and 7, complex karyotype or translocations involving 11q23, similar to that reported for t-MDS/AML. 7, 8 By the NCCSS criteria, 6 only two patients had 'very good' risk; therefore, this category was combined with the 'good' category and used as the reference group for analysis. In univariate and multivariate analysis of OS and DSS, the 'poor' and 'very poor', but not the 'intermediate' category, were significantly different from the reference category.
In addition, the 'poor' and 'very poor' categories were significantly or close to significantly different from one other in all analyses (Table 2 and Supplementary Table1).
Incorporating BM blast count, cytopenia(s) and cytogenetic findings into the IPSS-R scores, the distribution of five IPSS-R groups is shown in Table 2 . Notably, there were only 17 (4.3%) patients with a 'very low' score. The IPSS-R grouping stratified patients with respect to OS ( Figure 1a ) and DSS (Figure 1b) , and AML progression probability in t-MDS patients (Figure 1c) . However, the IPSS-R distribution appeared skewed towards higher-risk scores, as compared with reported 7012 de novo MDS/oligoblastic AML patients (Figure 1d ). The median OS for each IPSS-R-risk group was 56.5, 21.7, 15.8, 8.9 and 6.0 months (Figure 1e ) and the median DSS was not reached, 47.2, 22.6, 15.1 and 7.7 months. 
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We also analyzed the effect of additional factors on prognosis. Age, gender or the type of primary malignancy showed no significant association with OS or DSS (Supplementary Tables 1  and 2 ). Patients who received chemotherapy had similar survival to those who received chemoradiation, but inferior to patients who received radiation only in univariate and multivariate analysis (Supplementary Tables 1 and 2 ). In terms of the WHO classification, patients with t-refractory cytopenia with unilineage dysplasia (RCUD)/t-refractory anemia with ring sideroblasts (RARS)/t-refractory cytopenia with multilineage dysplasia (RCMD)/t-MDS-U (unclassifiable; categories with o5% BM blasts) had a more favorable OS and DSS than patients with t-RAEB-1/-2 and oligoblastic t-AML (Supplementary Table 2 ). However, multilineage (t-RCMD) versus unilineage (t-RCUD) dysplasia had no impact on OS or DSS either by univariate (P ¼ 0.610 and P ¼ 0.495, respectively) or multivariate (P ¼ 0.916 and P ¼ 0.527, respectively) analyses. There were no significant differences in OS or DSS between t-RAEB-1/RAEB-2 and oligoblastic t-AML (Supplementary Tables 1 and 2 ). A total of eight patients had MLL gene rearrangement confirmed by FISH, two of them in a complex karyotype. The median OS and DSS of these eight patients were 3.5 months (95% CI: 0.8-6.8), significantly worse than those without MLL rearrangement in univariate, but not multivariate analysis (Supplementary  Tables 1 and 2 ).
In summary, without an existing risk model for t-MN, we applied the recently revised IPSS (IPSS-R) to this large series of t-MDS and oligoblastic t-AML patients. We found that some IRSS-R cutpoints may not be optimal for t-MDS/oligoblastic t-AML patients. A binary cutpoint for hemoglobulin at 10 g/dl and platelets at 50 Â 10 9 /l may be more appropriate; and ANC did not appear to contribute to outcome in patients with t-MN. Importantly, in contrast to the importance of progressively increasing BM blast strata in IPSS/IPSS-R and the WHO categories in de novo MDS, a binary 5% BM blast cutpoint appeared to be sufficient in t-MDS/oligoblastic t-AML; once BM blasts exceed 5%, other factors such as cytogenetic risk 8 appear to be more important in determining the aggressiveness of t-MDS/oligoblastic t-AML. These findings are largely in accord with the current WHO classification in that a precise sub-classification of t-MDS may not be relevant. Similar findings have been observed in patients with acute erythroid leukemia 9, 10 and erythroid predominant MDS, 11 in which further blast count stratification in cases with X5% BM blasts no longer has impact on outcome. Karyotypic abnormalities were observed in 77.3% patients and were skewed towards higher NCCSS risk groups, with almost no patients in the 'very good' group. Although the 'poor' and 'very poor' cytogenetic-risk groups correlated with adverse survivals, the 'good/very good' and 'intermediate' categories showed similar survivals. The 'intermediate' category contains miscellaneous karyotypic abnormalities, and the clinical impact of individual chromosomal aberrancy may require further study in the therapy-related setting. For example, our data suggest that MLL gene rearrangement, which is rare in de novo MDS and was not captured by the IPSS-R, might belong to the 'very high' risk category in t-MDS/oligoblastic t-AML patients. Abbreviations: ANC, absolute neutrophil count; BM, bone marrow; CI, confidence interval; DSS, disease-specific survival; HR, hazard ratio; IPSS-R, International Prognostic Scoring System-revised; OS, overall survival. '-' denotes reference category for the Cox model. '\' stands for non-applicable. *P: compared with the reference group; **P: compared between the contiguous groups.
The overall IPSS-R scores separated t-MN patients into five risk groups, with each category showing statistical differences in OS, DSS as well as AML progression probability in t-MDS. These findings indicate that BM blast count, cytopenia(s) and cytogenetic data remain as powerful predictors in the therapy-related setting. However, compared to de novo MDS/oligoblastic AML, the median OS for each of the IPSS-R-risk group of patients was shorter in t-MDS/t-AML, particularly in the 'very low' and 'low' risk groups. These differences likely reflect a number of factors, including different biology and clinical approaches between t-MDS/oligoblastic t-AML and de novo disease. Prior cytotoxic exposures often cause high-risk cytogenetic abnormalities, as well as other genetic and epigenetic alterations of hematopoietic stem cells, that may underlie chemoresistance and poor responses to conventional therapy or early relapse in affected patients. 2, 8, 12, 13 In keeping with our prior study, 14 we showed that patients with t-MDS/oligoblastic t-AML secondary to radiation therapy alone had better outcomes than those secondary to chemotherapy/chemoradiation. These data challenge whether MDS or AML following radiation therapy alone are all therapy related: many may be coincidental or reflect individual predispositions to cancer. In contrast to the IPSS-R model, which was limited to patients who received no diseasealtering therapy, many our patients received chemotherapy and/or hypomethylating agents. Although different treatment modalities other than HSCT did not seem to impact survivals in our study (Supplementary Figure 1) , the possibility that therapy choice may contribute to the poor patient outcome of t-MDS/oligoblastic t-AML versus de novo disease cannot be excluded. Notably, our patients who received HSCT demonstrated a significant better OS (Supplementary Figure 1) and DSS (data not shown); the effectiveness of IPSS-R in predicting HSCT outcome in t-MDS/oligoblastic AML patients would be of interest in future large cohort studies.
In summary, IPSS-R parameters, including blasts, cytopenia(s) and cytogenetic data, are powerful predictors in patients with t-MDS/oligoblastic AML, but their optimal application to predicting outcome in t-MDS/oligoblastic AML requires certain modifications. As more information on molecular genetic changes in MDS and AML patients become available, 15 the additional impact of gene mutations on risk stratification in patients with t-MN will need to be evaluated. Our results suggest that predicting t-MDS/oligoblastic AML aggressiveness in order to make riskadapted therapeutic decisions can in part be based on many of the factors applied to patients with de novo disease. and AML progression probability in t-MDS patients (c). Notably, the IPSS-R-risk distribution in t-MDS/oligoblastic t-AML patients is skewed towards higher-risk groups compared with de novo MDS/oligoblastic AML (n ¼ 7,012) (d). The median OS of patients with t-MDS/ oligoblastic t-AML in the respective IPSS-R categories was 56.5, 21.7, 15.8, 8.9 and 6.0 months, in contrast to those reported on de novo MDS/ oligoblastic AML patients (n ¼ 7,012) 5 (105.6, 63.6, 36, 19.2 and 9.6 months, respectively (e).
